EP4291279A1 - Medical shunts - Google Patents
Medical shuntsInfo
- Publication number
- EP4291279A1 EP4291279A1 EP22753294.2A EP22753294A EP4291279A1 EP 4291279 A1 EP4291279 A1 EP 4291279A1 EP 22753294 A EP22753294 A EP 22753294A EP 4291279 A1 EP4291279 A1 EP 4291279A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- elongated member
- medical device
- anchor
- shunt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003754 fetus Anatomy 0.000 claims abstract description 40
- 210000003815 abdominal wall Anatomy 0.000 claims abstract description 13
- 239000012530 fluid Substances 0.000 claims description 21
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 9
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 9
- 239000013013 elastic material Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 14
- 238000013461 design Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 229920003266 Leaf® Polymers 0.000 description 5
- 210000004381 amniotic fluid Anatomy 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241000219793 Trifolium Species 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010046479 Urethral valves Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 208000001184 Oligohydramnios Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 241000722921 Tulipa gesneriana Species 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 210000005068 bladder tissue Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000005952 Amniotic Fluid Embolism Diseases 0.000 description 1
- 206010060937 Amniotic cavity infection Diseases 0.000 description 1
- 206010067010 Anaphylactoid syndrome of pregnancy Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000025299 Atresia of urethra Diseases 0.000 description 1
- 208000008158 Chorioamnionitis Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010020524 Hydronephrosis Diseases 0.000 description 1
- 208000006031 Hydrops Fetalis Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 206010066239 Mediastinal shift Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010036603 Premature rupture of membranes Diseases 0.000 description 1
- 206010037407 Pulmonary hypoplasia Diseases 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010064895 Urethral atresia Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 208000019812 amnionitis Diseases 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 208000019244 fetal lower urinary tract obstruction Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
- A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
- A61M2027/004—Implant devices for drainage of body fluids from one part of the body to another with at least a part of the circuit outside the body
Definitions
- the field ofthe subject disclosure relates to medical devices, and more specifically medical shunts, such as vesicoamniotic shunts (VAS), thoraco-amniotic shunts, etc.
- VAS vesicoamniotic shunts
- thoraco-amniotic shunts etc.
- Anhydramnios in turn results in irreversible pulmonary hypoplasia and pulmonary hypertension due to extrinsic compression of the uterine wall on the devdoping fetal chest It is also thought that fetal swallowing of amniotic fluid assists wife normal lung devdopment although fee precise mechanism of this remains unclear. Without in-utero feerapy, LUTO is associated wife an 80% mortality rate, mostly due to pulmonary injury incompatible wife life.
- shunts In the Lucile Packard Children’s Hospital (LPCH) experience, shunts have internalized completely within the fetal bladder or even the peritoneum, requiring surgical removal after birth. Alternatively, shunt migration out of the abdominal wall has led to implantation within the uterine wall or free-floating shunts in the amniotic cavity found during delivery. Even worse, there have been reports of shunt coils wrapping around a limb or umbilical cord compromising limb or life.
- VAS can be utilized for fetal treatment of LUTO, improving amniotic fluid volume and in-utero pulmonary development, the effects on renal impairment remain largely unknown. Furthermore, the inherent technical limitations of existing shunts and the risks of performing an invasive procedure via the maternal abdomen limit fetal therapy to the most severe LUTO cases. Furthermore, current VAS has been known to dislodge or migrate from its desired position relative to the patient after the VAS has been delivered.
- Embodiments of shunt described herein address these current limitations with improved surgical specifications, reduced complications risks and a built-in mechanism to optimize in-utero bladder/renal function. Embodiments of shunt described herein may also improve survival as well as pulmonary and renal outcomes.
- a medical device includes: an elongated member having a first end, a second end, and a body extending between the first end and the second end; a first anchor coupled to the first end of the elongated member; and a second anchor coupled to the second end of the elongated member; wherein the elongated member is configured for placement across an abdominal wall of a fetus, and wherein the elongated member is elastically stretchable to accommodate for a growing thickness of the abdominal wall of the fetus.
- the elongated member comprises a lumen extending from the first end to the second end.
- the elongated member is kink resistant.
- the elongated member comprises a coil, a braid, or a laser-cut tubing.
- the coil or the braid of the elongated member is made from an elastic material.
- the first anchor comprises a braided element.
- the braided element is configured to assume a delivery configuration when the braided element is contained in a delivery device, and to assume a deployed configuration when the braided element is outside the delivery device.
- the braided element is configured to expand radially when outside the delivery device.
- the braided element is made from Nitinol.
- the second anchor comprises a braided element.
- the first anchor comprises a plurality of leaflet elements.
- the leaflet elements are configured to assume a delivery configuration when the leaflet elements are contained in a delivery device, and to assume a deployed configuration when the leaflet elements are outside the delivery device.
- the medical device further includes a one-way valve coupled to the elongated member.
- the one-way valve is located in a lumen of the elongated member.
- the one-way valve is located at the first end or at the second end.
- the one-way valve is located closer to the first end than to the second end, or vice versa.
- the one-way valve is configured to open in response to pressure that is above a certain threshold.
- the medical device further includes a pressure sensor, wherein the one-way valve is configured to open based on input provided by the pressure sensor.
- a medical device includes: an elongated member having a first end, a second end, and a body extending between the first end and the second end; and a first anchor coupled to the first end of the elongated member; wherein the first anchor comprises a braided element; wherein the braided element is configured to assume a delivery configuration when the braided element is contained in a delivery device, and to assume a deployed configuration when the braided element is outside the delivery device.
- the first end is configured for placement inside a patient
- the second end is configured for placement outside the patient.
- the medical device further includes a second anchor coupled to the second end of the elongated member.
- the second end of the elongated member is configured to couple to a drainage container.
- a medical device includes: an elongated member having a first end, a second end, and a body extending between the first end and the second end; a first anchor coupled to the first end of the elongated member; and a one-way valve located in a lumen of the elongated member.
- the medical device further includes a second anchor coupled to the second end of the elongated member.
- the first end is configured for placement inside a patient
- the second end is configured for placement outside the patient.
- the second end of the elongated member is configured to couple to a drainage container.
- a medical device includes: an elongated member having a first end, a second end, and a body extending between the first end and the second end; and a first anchor coupled to the first end of the elongated member; wherein the elongated member is configured for placement between fluid from a first body cavity of a patient to a second body cavity of the patient or to a location outside the patient.
- FIG. 1 illustrates a shunt and deliver device for delivering the shunt.
- FIG. 2 illustrates a one-way valve that may be incorporated into the shunt of
- FIG. 3 illustrates the shunt of FIG. 1, having been deployed to treat a fetus.
- FIG. 4 illustrates a variation of the shut of FIG. 1.
- FIGS. 5A-5C illustrate another variation of the shunt of FIG. 1.
- FIG. 6 illustrates design features for the shunt for addressing different needs.
- FIG. 7 illustrates alternative shunt solutions.
- FIG. 8 illustrates testing setup and testing results for different shunts.
- FIG. 9 illustrates a shunt flow test fixture.
- FIG. 10 illustrates an apparatus for testing a shunt.
- FIG. 11 illustrates the shunt device of FIG. 1 without any one-way valve.
- FIG. 12 illustrates the shunt device of FIG. 1, particularly showing a variation of the design of the one-way valve.
- FIGS. 13A-13E illustrate a technique of deploying the shunt of FIG. 1.
- a medical device 10 (e g., shunt) includes: an elongated member 20 having a first end 22, a second end 24, and a body 26 extending between the first end 22 and the second end 24; a first anchor 30 coupled to the first end 22 of the elongated member 20; and a second anchor 40 coupled to the second end 24 of the elongated member 20 (See FIG. 1).
- the elongated member 20 is configured for placement across an abdominal wall of a fetus, or other fetal organ.
- the first anchor 30 is configured for placement inside a bladder of the fetus
- the second anchor 40 is configured for placement outside the fetus in the amniotic cavity.
- first anchor 30 may be considered as a bladder anchor
- second anchor may be considered as an amniotic anchor.
- the anchors 30, 40 are made from braided Nitinol in the illustrated embodiments. In other embodiments, the anchors 30, 40 may have other form, and/or may be made from other materials.
- the shunt 10 may optionally further include a one-way valve 60 (e.g., a one-way duckbill valve made from silicone) coupled to the elongated member 20.
- the one-way valve 60 allows fluid (e.g., urine) to be transported from inside the patient to outside the patient, and also prevents the exited urine from flowing back to inside the patient.
- the one-way valve 60 may be configured to simulate the urinating functionality and/or urinating schedule or urinating frequency of a human.
- the one-way valve 60 may be located in the elongated member 20. In some cases, the one-way valve 60 may be located closer to the anchor 30 than to the anchor 40.
- the one-way valve 60 may be located closer to the anchor 40 than to the anchor 30. In further embodiments, the one-way valve 60 may be located at a location that is the midpoint between the anchors 30, 40. In some embodiments, the one- way valve 60 is located at the first end 22 or at the second end 24. In other embodiments, the one-way valve 60 is located closer to the first end 22 than to the second end 24, or vice versa. In further embodiments, the one-way valve 60 may be located at the anchor 30 or at the anchor 40.
- the one-way valve 60 is configured to open in response to pressure that is above a certain threshold.
- the threshold may be selected to simulate a physiological pressure associated with bladder emptying.
- the shunt 10 may further include a pressure sensor, wherein the one-way valve 60 is configured to open based on input provided by the pressure sensor.
- the opening and/or closing of the valve 60 may be controlled by an external device that communicates with a switch at the valve. The communication may be achieved via a signal transmitter.
- the external device may be a computer, a cell phone, a hand-held controller, etc.
- the shunt 10 may include any of other types of valve. In further embodiments, the shunt 10 may not include the one-way valve 60.
- the anchor 30 extends radially away from the elongated member 20. This feature also helps secure the anchor 30 inside the patient.
- the anchor 40 extends radially away from the elongated member 20. This feature helps secure the anchor 40 outside the patient.
- the anchors 30, 40 have the same cross-sectional dimension.
- the anchor 30 may have a cross-sectional dimension that is larger than a cross-sectional dimension of the anchor 40.
- the anchor 30 may have a cross-sectional dimension that is smaller than a cross-sectional dimension of the anchor 40.
- one or both of the expanded anchors 30, 40 may have a cross-sectional dimension that is anywhere from 4 mm to 20 mm, and more preferably, anywhere from 10 mm to 15 mm.
- the expanded anchors 30, 40 may have the same cross-sectional dimension.
- the expanded anchors 30, 40 may have different respective cross-sectional dimensions.
- the expanded anchor 30 may have a cross-sectional dimension that is anywhere from 12 mm to 16 mm (e.g., 14 mm)
- the expanded anchor 40 may have a cross-sectional dimension that is anywhere from 8 mm to 11 mm (e.g., 10 mm).
- the anchor 30 curves distally (e.g., away from the first end 22 of the elongated member 20 towards the second end 24). This way, at least a part of the anchor 30 lies in a plane intersecting the elongate member 20 at a location that is between the first end 22 and the second end 24. In other embodiments, the anchor 30 may curves proximally. In further embodiments, the anchor 30 may lie in a plane. In such cases, the anchor 30 does not curve distally and does not curve proximally. Similarly, as shown in the figure, the anchor 40 curves proximally (e.g., away from the second end 24 of the elongated member 20 towards the first end 22).
- the anchor 40 lies in a plane intersecting the elongate member 20 at a location that is between the first end 22 and the second end 24.
- the anchor 40 may curves distally.
- the anchor 40 may lie in a plane. In such cases, the anchor 40 does not curve distally and does not curve proximally.
- a delivery device 50 may be provided for delivery of the shunt 10.
- the delivery device 50 has a channel for housing the shunt 10.
- the shunt 10 has a delivery configuration inside the delivery device 50, in which the anchors 30, 40 (and optionally the elongated member 20) are stretched and/or bent to have a low profile. After the shunt 10 is delivered, the anchors 30, 40 will assume an expanded profile.
- the delivery device 50 may optionally further include a Touhy Borst adaptor to assist delivery of the shunt 10.
- the shunt 10 is housed inside the delivery device 50, and the shunt 10 has a delivery configuration inside the delivery device 50.
- the delivery device 50 has a sharp distal tip 52 configured to pierce through a skin of the mother of the fetus, and through a wall of the uterus and the amniotic sac.
- an insertion trocar may be utilized for insertion and/or placement of the delivery device 50.
- the delivery device 50 is also configured to pierce through an abdominal wall of the fetus, and through the detrusor muscle to access an inner space of the bladder of the fetus.
- the shunt 10 is then advanced distally relative to the delivery device 50, and/or the delivery device 50 is moved proximally relative to the shunt 10, until the first anchor 30 is outside the delivery device 50.
- the first anchor 30 expands radially to assume a deployed configuration.
- the first anchor 30 is configured to anchor against an inner wall of the bladder (FIG. 3).
- the delivery device 50 is moved proximally to expose the elongated member 20, and to deploy the second anchor 40.
- the second anchor 40 is deployed outside the fetus (e.g., in the uterine cavity / amniotic fluid) so that the second anchor 40 anchors against a skin of the fetus (FIG. 3).
- ultrasound may be used to guide suprapubic placement of an insertion trocar.
- the shunt 10 may then be deployed.
- the placement of the shunt 10, and successful drainage of urine (from inside the bladder to outside the fetus) via the elongated member 20 may also be confirmed with ultrasound.
- the shunt 10 is not limited to the above configuration, and that the shunt 10 may have other configurations in other embodiments.
- the first anchor 30 may have a spiral configuration
- the second anchor 40 may have a spiral configuration (FIG. 4).
- the elongated member 20 may also have a spiral configuration as shown in the figure.
- the spiral configuration of the elongated member 20 allows the elongated member 20 to change shape in correspondence to a varying distance between the anchors 30, 40.
- the elongated member 20 may be stretched to accommodate movement of the uterus, and/or in-utero growth of the fetus.
- the elongated member 20 may be kink-resistant while changing shape to increase the length along the longitudinal axis of the shunt 10.
- the elongated member 20 may have a length (e.g., total length) that is anywhere from 10 mm to 30 mm, and more preferably anywhere from 15 mm to 25 mm (e.g., 20 mm). In other embodiments, the elongated member 20 may have a length (e.g., total length) that is more than 30 mm, or less than 10 mm. Also, in some embodiments, the elongated member 20 may have a nominal length L (unstretched length), and may be stretchable to reach a total length that is at least: 1.2L, or 1.3L, or 1.4L, or 1.5L, or 1.6L, or 1.7L. For example, in some embodiments, the elongated member may have a nominal length of 20 mm, and may have an extended length of 30 mm.
- L unstretched length
- the anchor 30 is a spiral tube with a lumen therein, wherein the lumen of the spiral tube is in fluid communication with a channel (conduit) in the elongated member 20.
- the anchor 40 is a spiral tube with a lumen therein, wherein the lumen of the spiral tube is in fluid communication with the channel (conduit) in the elongated member 20.
- Each of the spiral tubes of the respective anchors 30, 40 has a plurality of holes. During use, urine from the bladder may enter into the holes at the spiral tube of the anchor 30. The urine goes through the one-way valve 60 inside the conduit of the elongated member 20 as the elongated member 20 transports the urine to the anchor 40. The urine then exits the openings at the spiral tube of the anchor 40.
- the anchor 30 has a spiral configuration in which the member forming the anchor 30 has multiple turns (or loops) with different radius of curvatures.
- the elongated member 20 is connected to a part of the anchor 30 that has a relative smaller radius of curvature compared to another part of the anchor 30. This feature is advantageous as it may assist the anchor 30 in staying inside the patient so that the shunt 10 will not be dislodged. If the elongated member 20 is connected to the part of the anchor 30 that has the largest radius of curvature, the anchor 30 may be easily pulled out from the patient.
- the anchor 40 has a spiral configuration in which the member forming the anchor 40 has multiple turns (or loops) with different radius of curvatures.
- the elongated member 20 is connected to a part of the anchor 40 that has a relative smaller radius of curvature compared to another part of the anchor 40. This feature is advantageous as it may assist the anchor 40 in staying outside the patient. If the elongated member 20 is connected to the part of the anchor 40 that has the largest radius of curvature, at least a part of the anchor 40 may migrate inside the patient.
- the spiral configuration of the anchor 30 has an increasing radius of curvature as so that the member forming the anchor 30 extends radially away from the elongated member 20. This feature also helps secure the anchor 30 inside the patient.
- the spiral configuration of the anchor 40 has an increasing radius of curvature as so that the member forming the anchor 40 extends radially away from the elongated member 20. This feature helps secure the anchor 40 outside the patient.
- the anchor 30 curves distally (e.g., away from the first end 22 of the elongated member 20 towards the second end 24).
- the anchor 30 lies in a plane intersecting the elongate member 20 at a location that is between the first end 22 and the second end 24.
- the anchor 30 may curves proximally.
- all of the loops of the anchor 30 may lie in a same plane. In such cases, the anchor 30 does not curve distally and does not curve proximally.
- the anchor 40 curves proximally (e.g., away from the second end 24 of the elongated member 20 towards the first end 22). This way, at least a part of the anchor 40 lies in a plane intersecting the elongate member 20 at a location that is between the first end 22 and the second end 24. In other embodiments, the anchor 40 may curves distally. In further embodiments, all of the loops of the anchor 40 may lie in a same plane. In such cases, the anchor 40 does not curve distally and does not curve proximally.
- the anchors 30, 40 made be made from a material that is different from the material of the elongated member 20. In other embodiments, the anchors 30, 40 and the elongated member 20 may be made from the same material. In one implementation, a tubular structure may be utilized to form the elongated member 20 and the anchors 30, 40.
- the first anchor 30 may have a plurality of leaflet elements forming a “Tulip” (or “clover”) design
- the second anchor 40 may also have a plurality of leaflet elements (FIG. 5 A).
- the elongated member 20 is a tube with a thin wall made from an elastic material (e.g., silicone, PET, etc.).
- the elongated member 20 may be implemented using a superelastic nitinol coil covered by a thin wall made from a stretchable material (e.g., silicone, PET, etc.).
- the shunt 10 also includes a first opening 500 at the first anchor 30, a second opening 502 at the second anchor 40, and a channel (conduit) in the elongated member 20 extending between the first opening 500 and the second opening 502.
- the 4-leaf clover design of the anchor 30 is configured to anchor against the bladder, while the 4-leaf clover design of the anchor 40 is configured to anchor against the abdominal wall.
- the anchor 30 and/or the anchor 40 may be made of ePTFE which has a different echogenicity due to its foam like material, allowing for accurate placement intraoperatively.
- the anchors 30, 40 may be made from other materials.
- the leaflets of the anchors 30, 40 are folded while the shut 10 is contained inside the delivery device 50. After the shunt 10 is deployed outside the delivery device 50, the leaflets of the anchors 30, 40 open up radially to assume respective expanded configurations. In some cases, the anchors 30, 40 may be folded into the trocar and then expand into the clover configuration after the shunt 10 is deployed.
- the anchors 30, 40 may have different shapes and/or sizes, which allow them to be differentiated in imaging. In other embodiments, the anchors 30, 40 may have the same shape and size. In such cases, different markers may be coupled to the respective anchors 30, 40 to allow them to be differentiated in imaging. In other embodiments, different portions of the respective anchors 30, 40 may have respective echogenicities of different shapes. This will also allow the anchors 30, 40 to be differentiated in imaging.
- each of the anchors 30, 40 is the form of a leaflet system having four leafs.
- each anchor 30/40 may have two or three leafs, or more than four leafs.
- the tulip design and the braid design may be more advantageous than the spiral design for the anchor 30 because they may be more resistant to dislodgement - i.e., such designs allow the anchor 30 to be more secured inside the bladder so that the anchor 30 will not come out of the patient by itself.
- the elongated member 20 may be flexible in bending while being kink resistant.
- the elongated member 20 is also elastic in its axial direction to allow the elongated member 20 to undergo sufficient strain in order to accommodate fetus movement and/or growth of the fetus.
- the elongated member 20 may be made from a material and/or may include a reinforcing layer (e.g., a wire mesh, a coil, etc.), which provides the kink-resistant characteristic.
- the elongated member 20 remains flexible while having the kink-resistant characteristic.
- the shunt 10 is not limited to the above examples, and may have other features and/or combination of features.
- the elongated member 20 of the shunt 10 is elastically stretchable to accommodate for a growing thickness of the abdominal wall of the fetus.
- the elongated member 20 of the shunt 10 may be a coil element.
- the coil element may be configured to be delivered in an extended state, and contract upon deployment to bring two fluid communicating regions together/appose.
- the elongated member 20 of the shunt 10 may comprise a lumen extending from the first end 22 to the second end 24.
- the elongated member 20 of the shunt 10 may be kink resistant.
- the elongated member 20 of the shunt 10 may comprise a coil, a braid, or a laser-cut tubing.
- the coil or the braid of the elongated member 20 may be made from an elastic material (e.g., polymer, metal, alloy, etc.).
- the coil or the braid of the elongated member 20 may be made from Nitinol.
- the elongated member 20 of the shunt 10 may be a coil reinforced member, and may include a channel for transportation of fluid.
- the elongated member 20 may be a tube made from PET, and may have a reinforcement layer in the tube, wherein the reinforcement layer may be made from Nitinol.
- the elongated member 20 of the shunt 10 may be biocompatible.
- the elongated member 20 may be 4Fr, 5Fr, 6Fr, or any of other sizes.
- the elongated member 20 of the shunt 10 may be flexible in the bending and axial direction, while being kink-resistant.
- the elongated member 20 of the shunt 10 may have a memory shape.
- the elongated member 20 of the shunt 10 when the elongated member 20 of the shunt 10 is contained in the delivery device 50, the elongated member 20 is stretched / compressed into a low profile.
- the elongated member 20 When the elongated member 20 is delivered outside the delivery device 50, the elongated member 20 assumes its delivery shape (memory shape).
- the first anchor 30 of the shunt 10 may comprise a braided element.
- one or both of the anchors 30, 40 of the shunt 10 may be partially or completely covered with an impermeable, biocompatible element. [0093] In some embodiments, one or both of the anchors 30, 40 of the shunt 10 may be atraumatic.
- one or both of the anchors 30, 40 of the shunt 10 may be echogenic.
- one or both of the anchors 30, 40 of the shunt 10 may be made from a foam.
- one or both of the anchors 30, 40 may of the shunt 10 be made from ePTFE.
- one or both of the anchors 30, 40 may include leaflets made from a foam, and supports (for the leaflets) made from FEP.
- the anchor 30 / 40 may extend radially away from the elongated member 20.
- the radial extension may be in one direction, or in multiple directions.
- the anchor 30 / 40 may have a dome shape.
- the shunt 10 may be coated with a pharmacological agent.
- some or all shunt 10 components may be biodegradable.
- the braided element of the anchor 30 / 40 is configured to assume a delivery configuration when the braided element is contained in the delivery device 50, and to assume a deployed configuration when the braided element is outside the delivery device 50.
- the braided element is configured to expand radially when outside the delivery device 50.
- the braided element is made from an elastic material (e.g., polymer, metal, alloy, etc.).
- the second anchor 40 of the shunt 10 may comprise a braided element.
- one or each of the first and second anchors 30, 40 of the shunt 10 has a plurality of fluid communicating regions.
- one or each of the first and second anchors 30, 40 of the shunt 10 may have concave or convex.
- the first anchor 30 of the shunt 10 may comprise a plurality of leaflet elements.
- the leaflet elements are configured to assume a delivery configuration when the leaflet elements are contained in the delivery device 50, and to assume a deployed configuration when the leaflet elements are outside the delivery device 50.
- At least a part of the shunt 10 may be echogenic (e.g., at least a part of the shunt 10 may incorporate echogenic enhancements).
- the delivery device 50 may be coupled to the shunt 10 to facilitate positioning, controlled release of the shunt 10, and recapturing of the shunt 10.
- the coupling may be threaded, magnetic, electronically actuated, or other mechanical coupling.
- the delivery device 50 may be a 4Fr, 5Fr, 6Fr, 7Fr, or 8Fr delivery device.
- a medical system may include the shunt 10 and an insertion trocar.
- shunts 10 there may be different shunts 10 with different respective sizes.
- one or more of the below features of the shunt 10 may be optimized: 1) anchoring features that maintain the positional stability of the shunt 10 for the duration of the implant, 2) shunt conduit through which fetal urine will pass, 3) a one-way valve to maintain a pre-determined bladder pressure and allow urine to pass once that pressure is exceeded, and 4) the delivery system and method.
- the shunt 10 may be made from a variety of materials.
- at least a part of the first anchor 30, at least a part of the second anchor 40, and/or at least a part of the elongated member 20, may be made from Nitinol, such as Nitinol wire (NDC Freemont, CA), Nitinol Coils/braids (Kellogg Research Group Nashua, NH), etc.
- Nitinol material allows the shunt 10 to be visualized via imaging (e.g., ultrasound) during delivery of the shunt 10.
- the elongated member 20 may be made from polymeric extrusion(s) (Duke Empirical Santa Cruz, CA).
- polymer(s) may be applied onto the elongated member 20 by coating the elongated member 20 in an elastic polymer (e.g. polyurethane or other biocompatible elastomer), by covering the elongated member 20 with a polymer incorporating pleats (which allow for axial expansion), or by a combination of the above techniques.
- an elastic polymer e.g. polyurethane or other biocompatible elastomer
- a polymer incorporating pleats which allow for axial expansion
- the braided anchors 30, 40 are advantageous because they can assume a low profile while contained inside the delivery device 50, and can expand radially to form expanded anchors 30, 40.
- the low profile of the braid anchor also prevents the fetus from grasping and/or dislodging the shunt 10.
- the braided anchor 30 inside the fetus is also advantageous because the openings and porosity of the braided anchor 30 allows fluid to enter into the anchors 30 (like a storm drain tubing), and be received by the lumen inside the elongated member 20.
- the axially adjustable feature of the elongated member 20 is advantageous because it allows the delivered shunt 10 to accommodate with the growing geometry and movement of the fetus. Also, the echogenicity feature of the shunt 10 allows it to be positioned and delivered efficiently and accurately. In addition, the one-way valve 60 is beneficial because it prevents fluid drained from the bladder of the fetus from entering back into the bladder.
- the shunt 10 may be designed according to one or more of the user’s needs summarized in the left column of FIG. 6.
- the shunt 10 may have one or more of the features stated in the right column of FIG. 6.
- the shunt 10 may be designed to have a size smaller than existing solutions, in order to reduce risk of premature membrane rupture, and to decrease incision size.
- the shunt 10 may have a size that is less than 3 mm, less than 2 mm, less than 1 mm, etc., when being delivered by the delivery device 50.
- the shunt 10 may have a securing mechanism designed to secure to an interior bodily region (e.g., bladder wall) of a patient.
- the securing mechanism may include one or more coils (e.g., nesting coils), a balloon, an anchor with a butterfly- configuration, an anchor with an umbrella configuration, a malegcot, etc.
- the securing mechanism may be configured so that the anchor pull-out force is higher than 0.35 Ibf, higher than 0.4 Ibf, higher than 0.5 Ibf, higher than 0.6 Ibf, higher than 0.7 Ibf, higher than 0.8 Ibf (e.g., 0.84 lb), etc.
- the shunt 10 may have a pull-out force that is more than 2 times, more than 4 times, more than 10 times, or more than 20 times than that of another shunt solution.
- another shunt solution has a pigtail coil or a double pigtail coils that can easily be pulled out.
- the shunt 10 may include a one-way valve configured to allow cyclic bladder emptying based on a pressure threshold. This feature may improve bladder muscle function, and may prevent backflow of urine.
- the shunt 10 may be designed to have a securing mechanism that can easily be reversed to collapse the shunt 10, and to retract the shunt 10. For example, at birth, the shunt 10 can be easily removed without causing damage to the baby.
- a retriever may be coupled to the shunt 10, and may retract the shunt 10 into a sheath.
- the retriever may have a coupler (e.g., a threaded attachment) configured to attach to an end of the shunt 10.
- the elongated member 20 may be designed to have a variable length, so that the elongated member 20 can change length in-vivo. This allows the fetus to move and to grow without interfering with the functionality of the shunt 10.
- the anchor 40 may have a deployed shape that remains flush with the abdominal wall of the fetus after deployment. This feature avoids limb entanglement, and may prevent the fetus from pulling out the shunt 10.
- the shunt 10 may be preloaded in a trocar. This may optimize workflow to decrease the number of steps required for placement of the shunt 10.
- the shunt 10 may be echogenic, which allows one or more components of the shunt 10 to be visualized by imaging.
- the anchors 30, 40, and/or the elongated member 20 may be echogenic in some embodiments.
- the shunt 10 may be echogenic so that it is viewable via medical imaging.
- at least a part of the elongated member 20, at least a part of the anchor 30, at least a part of the anchor 40, or any combination of the foregoing, may be made from a material that is echogenic.
- the shunt 10 is not required to have all of the above features described with reference to FIG. 6, and that the shunt 10 may have only one, or selected ones of the features.
- the embodiments of the shunt 10 described herein are significant improvements over the pigtail design or the double pigtail coils shown in FIG. 7.
- the shunts do not have dynamically adjustable elongated member that accommodates a growth of the fetus.
- the shunts of FIG. 7 also do not have any one- way pressure valve to facilitate in-utero intermittent bladder cycling allowing the development of normal bladder contractility.
- the shunts of FIG. 7 have less pull-out force - which means that the shunts can be easily pulled out.
- an apparatus may be provided to perform force testing for the shunt 10.
- FIG. 8 illustrates an example of such apparatus 800.
- the apparatus 800 includes a force gauge 802 configured to determine how much force is being applied on the shunt 10.
- the apparatus 800 also includes a tissue mount 810 configured to mount an artificial tissue, such as a porcine bladder 820 (available at Animal Technologies, Tyler TX).
- the porcine bladder 820 is configured to simulate a neonatal bladder.
- the force gauge 802 is supported on bearing 830 so that the force gauge 802 is moveable relative to the tissue mount 810 (and relative to the porcine bladder 820 secured by the tissue mount 810).
- the porcine bladder 820 is secured at the tissue mount 810.
- the shunt 10 is then loaded and the anchor 30 of the shunt 10 is deployed into the porcine bladder 820 to simulate an interaction between the shunt 10 and a bladder.
- the force gauge 802 is attached to the proximal end of the shunt 10, and the force gauge 802 is translated on the bearing 830.
- the movement of the force gauge 802 pull the proximal end of the shunt 10 proximally, thereby applying force onto the shunt 10.
- the force applied onto the shunt 10 increases. Initially, when the force is low, the anchor 30 stays inside the porcine bladder 820. When sufficient force is applied onto the shunt 10, the anchor 30 of the shunt 10 will be pulled out from the porcine bladder 820.
- a model bladder test chamber may be provided to test the patency of the shunt design iterations and characterize release pressure using a porcine bladder tissue mounted to an open-manometer pressure chamber (FIG. 9).
- the model bladder test chamber includes a circular frame holding a layer of porcine bladder tissue.
- the model bladder test chamber also includes a tank modeling the bladder, and water in the tank modeling urine. This testing fixture may be utilized to test the valve mechanism (e.g., the one-way valve 60) of the shunt 10, enabling bladder cycling of urine in a fashion similar to normal non-obstructed bladders. The bladder cycling will allow early and regular use of the detrusor muscle, preventing it from undergoing fibrosis and ultimately myogenic failure postnatally.
- another apparatus 1000 may be provided to test a shunt (e.g., the shunt 10).
- the apparatus 1000 includes a frame 1002 (e.g., made from aluminum or any of other materials), a test chamber 1010, a first layer 1020 of material for simulating a patient’s skin, and a second layer 1022 of material for simulating a bladder.
- the apparatus 1000 further includes a force gauge 802. The force gauge is configured to measure an amount of force being exerted on the shunt 10.
- the chamber 1010 is configured to test the performance of the one-way valve of the shunt 10.
- the chamber 1010 is sealed during use, and may enable a variety of bladder pressures to be simulated.
- the chamber 1010 may be utilized in a process to characterize and optimize the performance of the one-way valve of the shunt 10.
- the apparatus 1000 optionally further includes a plurality of indexing holes 1050 at die top of the test chamber, which allow the force testing to be performed on the shunt at a number of different displacement force angles (e.g. 0o, 15o, 30o, 45o).
- the apparatus 1000 may optionally further include a valve configured to adjust a pressure of the fluid contained inside the chamber 1010.
- the layers 1020, 1022 simulating the skin and bladder interfaces are contained inside the chamber 1010. Fluid simulating bladder pressure is also placed inside the chamber 1010.
- the force gauge 802 grasps one end of the shunt 10.
- the force gauge 802 made be moved relative to the layer 1022 (against which the anchor 30 is anchored), or the layer 1022 may be moved relative to the force gauge 802, to increase the force being applied to the shunt 10.
- the force is increased until the anchor 30 is pulled out from one side of the layer 1022 to the other side of the layer 1022.
- the force may then be recorded as the pull-out force for the shunt 10.
- the distance between the layers 1020, 1022 may be adjusted to simulate a movement of a patient, and/or to simulate a growing fetus. This allows the elongated member 20 to be tested to see if it can change size and/or shape to accommodate the growth and/or movement of a fetus. Furthermore, the fluid pressure in die chamber allows the one-way valve of the shunt 10 to be tested, and see if the valve will allow' fluid on one side of the layer 1022 (simulating the bladder interface) to pass dierethrough, and to exit via opening(s) at the anchor 40.
- the shunt 10 is not required to include the one-way valve 60.
- the shunt 10 may not include the one-way valve 60.
- the one-way valve 60 may have different designs in different embodiments.
- the one-way valve 60 is not required to have the configuration shown in FIG. 2.
- the one-way valve 60 may have the configuration shown in FIG. 12.
- fluid flow in one direction will force the flaps of the valve 60 to open, thereby allowing fluid to pass through the valve 60.
- fluid flow in the opposite direction will force the flaps pf the valve 60 to close, thereby preventing fluid from passing through the valve 60.
- FIG. 13A-13E illustrate a technique of deploying the shunt 10.
- a pusher 1300 in a form of a rod has a distal end 1302 with a coupler 1310 configured to couple to an end of the shunt 10.
- the shunt 10 is contained in the delivery device 50 (e.g., a sheath, a cannula, or any tubular structure) before the shunt 10 is deployed (FIG. 13B).
- the anchors 30, 40 is compressed and/or stretched to have a low profile.
- the delivery device 50 may have a sharp distal tip for piercing tissue.
- the delivery device 50 may be utilized to pierce through a skin of a patient carrying a fetus, through the wall of the uterus, through a skin of a fetus, and through a wall of the bladder to reach an inside of die bladder of the fetus. Then the pusher 1300 is advanced relative to the delivery device 50, and/or the delivery device 50 is retracted relative to die pusher 1300, so that the anchor 30 is deployed outside the delivery device 50 into the interior of the bladder of the fetus (see FIG. 13C, and FIG. 3).
- the delivery device 50 is retracted relative to the pusher 1300, so that the elongated member 20 is deployed outside the delivery device 50, to a position that is across the wall of the bladder and across a skin of the fetus.
- the delivery device 50 is then further retracted relative to the pusher 1300, so that the anchor 40 is deployed outside the delivery device 50, to a position that is outside the fetus (see, for example, FIG. 3).
- the pusher 1300 may- be operated (e.g., twisted) to detach the coupler 1310 from the shunt 10 (FIG. 13D).
- the delivery device 50 and the pusher 1300 may then be retracted to remove from the uterus, and from the patient carrying the fetus.
- the embodiments of the shunt 10 described herein are not limited for treating LUTO, and are not limited to being placed across the abdominal wall of the fetus. In other embodiments, the shunt 10 may be utilized to treat other conditions, and may be placed in any locations inside a patient.
- the shunt 10 may be used as a thoraco- amniotic shunt for the treatment of fetal pleural effusions, fetal hydrops, or macrocystic congenital lung lesions. Similar complications in the currently known treatment can arise including shunt dislodgment and fetal chest trauma. Therefore, percutaneous fetal lung shunt procedures are also reserved for the most severe cases in which extra fluid or a mass within the fetal thoracic cavity is large enough to cause mediastinal shift and organ compression. Thus, embodiments of the shunt described herein may be used in the lungs or other areas in a patient to treat any fetal conditions.
- one end of the shunt described herein will be placed in a fetal lung.
- one end of the shunt described herein will be placed in the fetal lung.
- one end of the shunt described herein will be placed in the fetal abdomen.
- embodiments of the shunt 10 described herein are not limited to treat conditions in fetus, and may be used to treat conditions in babies, children, and adults.
- embodiments of the shunt 10 described herein may be used to treat any condition where a fluid collection in a patient needs to be drained or diverted.
- the shunt 10 may be configured for use as a cardiovascular bypass graft, or an arteriovenous graft for hemodialysis.
- one end (e.g., the first end) of the shunt 10 may be placed inside the body of the patient, and the other end (e.g., the second end) of the shunt 10 may be placed outside the body of the patient.
- the second end of the shunt 10 outside the patient’s body may be configured to couple to a drainage container (e.g., collection bag, bottle, sampling tube, etc.).
- a drainage container e.g., collection bag, bottle, sampling tube, etc.
- the elongate member 20 of the shunt 10 may be a catheter with one end (e.g., the first end) coupled to the first anchor 30 for placement inside a patient, and the other end (e.g., the second end) being for placement outside the patient.
- the elongated member 20 may be configured to couple to a catheter or to a tube.
- the second end 24 of the elongated member 20 may be coupled to a tube, wherein the coupling may be permanent, or may be a detachable coupling.
- the shunt 10 may be used to drain or transport fluid from a first body cavity of a patient to a second body cavity of the patient.
- both anchors 30, 40 are configured for placement inside the patient.
- the first body cavity may be any cavity inside the patient, and so it is not limited to a bladder cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149647P | 2021-02-15 | 2021-02-15 | |
| PCT/US2022/015868 WO2022173865A1 (en) | 2021-02-15 | 2022-02-09 | Medical shunts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4291279A1 true EP4291279A1 (en) | 2023-12-20 |
| EP4291279A4 EP4291279A4 (en) | 2025-01-08 |
Family
ID=82837885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22753294.2A Pending EP4291279A4 (en) | 2021-02-15 | 2022-02-09 | MEDICAL SHUNTS |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4291279A4 (en) |
| WO (1) | WO2022173865A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040111050A1 (en) * | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
| US20070129755A1 (en) | 2005-12-05 | 2007-06-07 | Ovalis, Inc. | Clip-based systems and methods for treating septal defects |
| US20110184329A1 (en) * | 2010-01-22 | 2011-07-28 | Valentin Kramer | Composite Arterial-Venous Shunt System |
| CN106714698B (en) * | 2014-09-09 | 2020-11-03 | 奥特鲁泰克控股有限公司 | Flow-regulating device in the heart |
| WO2017136733A1 (en) * | 2016-02-04 | 2017-08-10 | The Trustees Of Columbia University In He City Of New York | Left ventricular coronary conduit to increase coronary blood flow in heart failure patients |
-
2022
- 2022-02-09 EP EP22753294.2A patent/EP4291279A4/en active Pending
- 2022-02-09 WO PCT/US2022/015868 patent/WO2022173865A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4291279A4 (en) | 2025-01-08 |
| WO2022173865A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4767961B2 (en) | System and method for surgical implant placement | |
| US8025656B2 (en) | Methods, systems and devices for performing gynecological procedures | |
| US7060038B2 (en) | Device for delivering a sensor to the endovascular system and method of use | |
| US6767358B2 (en) | Apparatus for engrafting a blood vessel | |
| EP1389073B1 (en) | Draining bodily fluids with a stent | |
| US7527651B2 (en) | Male urethral stent device | |
| US8419677B2 (en) | Balloon-tipped endoscopic system | |
| CN101917928B (en) | Partial cuff | |
| US20020062129A1 (en) | Insertion device for stents & methods for use | |
| JPH0454459B2 (en) | ||
| KR20080067952A (en) | Controlled delivery of stents and grafts | |
| JP2001500030A (en) | Device for maintaining urinary bowel depression | |
| EP1765184A2 (en) | Method and device for cavity obliteration | |
| WO2011102988A1 (en) | Anatomic needle system | |
| US20120203357A1 (en) | Urethral anastomosis device | |
| US20250050075A1 (en) | Medical shunts | |
| EP4291279A1 (en) | Medical shunts | |
| US20230173239A1 (en) | Lumen-apposing shunt device transporting fluid between two body cavities | |
| WO2025264892A1 (en) | Implantable medical closure device and flexible deployment device for deploying the same into vasculature | |
| KR20200088535A (en) | A catheter inserted into artery of arm to prevent abdominal bleeding having pressure sensor for measuring blood pressure and use method thereof | |
| CN206621389U (en) | Stomach bottom hemostasis device | |
| CN213465235U (en) | Biliary tract puncture drainage tube with metal support | |
| CN109431666B (en) | Intraoperative stent delivery devices and intraoperative stent systems | |
| WO2008057566A2 (en) | Attachable ultrasound imaging device | |
| CN112842643A (en) | Combined support, conveyor and system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230914 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20241210 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 25/00 20060101ALI20241204BHEP Ipc: A61M 27/00 20060101AFI20241204BHEP |